Perrigo announced that it has settled Hatch-Waxman litigation brought by Meda Pharmaceuticals and Cipla regarding Dymista azelastine HCl/fluticasone propionate nasal spray.
Meda’s NDA for Dymista was approved by the FDA for the treatment of allergic rhinitis in 2012. Meda was acquired by Mylan in 2016.
Perrigo Executive VP and President, Rx Pharmaceuticals, John Wesolowski commented, “This settlement is another example of our long-term investment in the development of difficult to manufacture products. The Rx team continues to drive the business for long-term benefits.”
Read the Perrigo press release.
